NCT03272425View on ClinicalTrials.gov

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

October 4, 2017

Study Completion Date

October 4, 2017

Conditions
Gout
Interventions
DRUG

lesinurad/allopurinol 200/300 FDC tablets

Test Drug

DRUG

lesinurad 200 mg

Comparator 1

DRUG

allopurinol 300 mg

Comparator 2

Trial Locations (1)

Unknown

CAEP - Centro Avançado de Estudos e Pesquisas Ltda., Campinas

Sponsors
All Listed Sponsors
lead

Ardea Biosciences, Inc.

INDUSTRY